Vitamin D status and its associations with rheumatoid arthritis in Korean women: the Korean National Health and Nutrition Examination Survey 2008–2014

Taeck-Hyun Lee¹, Woo Sung Jin¹, Juwon Park¹, Hyun-Hee Choi², Eun Jin Bae¹,*

¹Department of Family Medicine, Daedong Hospital, Busan, Korea
²Division of Leisure & Sports Science, Department of Exercise Prescription, Dongseo University, Busan, Korea

INTRODUCTION

Rheumatoid arthritis is the most common autoimmune disease found in about 1% of adults worldwide. Rheumatoid arthritis is caused by neutrophils, macrophages, T cells, B cells and dendritic cells infiltrating the synovium of joints and causing inflammation, it causes damage to bone and disability. Finally, it induces systemic complications such as cardiovascular and cardiopulmonary dysfunction, and reduces life expectancy by about 3–10 years (Alamanos and Drosos, 2005; Picerno et al., 2015). Rheumatoid arthritis is 2 to 3 times more common in females than males (Alamanos and Drosos, 2005). Although the pathogenesis of rheumatoid arthritis has not yet been elucidated, it is known that the interaction of genetic and environmental factors influences congenital and adaptive immunity, resulting in systemic inflammation (Picerno et al., 2015).

Vitamin D not only plays a major role in the regulation of bone mineral homeostasis but also plays a role in cell function such as cell proliferation, differentiation, apoptosis, and angiogenesis (Abourazzak et al., 2015).

Recently, appropriate level of vitamin D has been reported to reduce the risk of some chronic inflammatory or autoimmune conditions such as various cancers, infectious diseases, type 1 diabetes, multiple sclerosis, and autoimmune rheumatic disease (Agmon-Levin et al., 2013). Calcitriol or 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), an endogenous serum-active metabolite of vitamin D, is a kind of steroid hormone produced by cholesterol. Therefore, calcitriol has immunomodulatory properties such as glucocorticoid and gonadal hormones (Cutolo et al., 2011).

There are reports that low vitamin D intake is associated with the development of rheumatoid arthritis, or low serum vitamin D level is associated with disease activity or physical disability in rheumatoid arthritis (Haque and Bartlett 2010; Kerr et al., 2011; Merlino et al., 2004; Rossini et al., 2010). On the other hand,
there are reports that vitamin D levels in patients with inflammatory joint disease are not related to arthritis activity (Braun-Moscovici et al., 2011; Craig et al., 2010).

The purpose of this study was to investigate the effect of vitamin D levels on the prevalence of rheumatoid arthritis in Korean adult women and to investigate the association of vitamin D levels with pain level and quality of life in Korean adult women with rheumatoid arthritis using the Korean National Health and Nutrition Examination Survey (KNHANES) from the Korea Centers for Disease Control and Prevention (2015).

MATERIALS AND METHODS

Subjects

This study analyzed the data of 2008–2014 from KNHANES. The subjects were women aged 19 years or older who completed a health questionnaire on rheumatoid arthritis and evaluation of vitamin D (25-hydroxyvitamin D; 25(OH)D) status.

It was reported that osteoporosis or increased parathyroid hormone affects vitamin D level (Aloia et al., 2006), and parathyroid hormone has inverse correlation with the conversion of vitamin D (25(OH)D) to active form of vitamin D, calcitriol (1,25(OH)2D3) (Pagan and Pagana, 2010). Thus, in the present study, patients with osteoporosis were excluded from the study until the year 2012 when health questionnaires and examinations for related items were discontinued. Parathyroid hormone abnormalities were also excluded in cases of over 65 pg/mL, according to the previous study (Aloia et al., 2006). Vitamin D is metabolized to the active form of calcitriol (1,25 (OH)2D3) in the liver and kidneys (Christakos et al., 2012), thus, patients with renal insufficiency or liver cirrhosis (Abourazzak et al., 2015) or those with thyroid disease or those with creatinine levels above 2.0 mg/dL were also excluded (Hansen et al., 2014).

Study design

The subjects were divided into whole female or fertile period and postmenopausal period. In each group, subjects were divided into five groups using the 5th quintile according to the serum level of vitamin D. The odds ratios of the five groups of rheumatoid arthritis according to the level of vitamin D in the serum were checked and the degree of pain and quality of life of the rheumatoid arthritis patients were analyzed. Pain intensity was assessed by visual analogue scale (VAS) ranging from 0 to 100, and quality of life was assessed using the EQ-5D questionnaire.

Statistics

KNHANES was recommended to be analyzed by complex sampling design (Korea Centers for Disease Control and Prevention, 2015). Thus, in this study, weights of each year were multiplied by the ratio of the surveyed population by year to generate integrated weights.

Demographic information used frequency and descriptive statistics of complex sampling design. The odds ratio of rheumatoid arthritis according to the level of vitamin D was determined by complex sampling design logistic regression. The degree of pain and quality of life of patients with rheumatoid arthritis according to their vitamin D levels were determined by the complex sampling design general linear model.

In the analysis of odds ratio, pain level and quality of life, we compared the value of the 5th group with the highest vitamin D level, and the values of the remaining four groups and found that there was a statistically significant difference. When there is a statistically significant difference, the $P$ for trend of the complex sampling design general linear model is conducted to confirm the linear trend.

Age and body mass index are major risk factors for rheumatoid arthritis (Qin et al., 2015) and also affect vitamin D level (Derdezmis et al., 2011; Holick et al., 2007). Thus, age and body mass index were used as covariates to control the effect of age and obesity on the association of rheumatoid arthritis and vitamin D level. In model 1, only age was used as covariate, and in model 2, both age and body mass index were used as covariates.

The values of the continuous variables were expressed as mean (standard error; SE), and the results of complex sampling design logistic regression analysis showed odds ratio and 95% confidence intervals (CIs).

Statistical analysis was performed using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). All statistical significances were $P<0.05$.

RESULTS

Demographic information

A total of 2,162 unweighted subjects were included in the study and their mean vitamin D was 15.80 ng/mL and the prevalence of rheumatoid arthritis was 12.0%. The numbers of unweighted subjects in fertile period female was 1,179, the mean vitamin D was 14.54 ng/mL, and the prevalence of rheumatoid arthritis was 5.7%. The numbers of unweighted subjects in postmenopausal period female was 983, and their mean vitamin D...
was 17.92 Ng/mL, and prevalence of rheumatoid arthritis was 22.4%, both of which were higher than those of fertile period female (Table 1).

Association between rheumatoid arthritis and vitamin D status

The odds ratios of rheumatoid arthritis according to the level of total vitamin D in the whole female was statistically significantly lower in the lowest vitamin D group and the second lowest vitamin D group than in the group with the highest vitamin D before using covariance. However, after using the covariates, all of these statistical differences disappeared.

The results of the subdivided into fertile period female and postmenopausal period female showed that the odds ratio of rheumatoid arthritis according to the level of serum vitamin D was not statistically significant (Table 2).

Association between rheumatoid arthritis' VAS and vitamin D status

In whole rheumatoid arthritis female group, the difference in pain level was not statistically significant depending on the level of vitamin D, and also was not statistically significant in fertile period rheumatoid arthritis female group.

In postmenopausal period rheumatoid arthritis female group, the third highest vitamin D group had significantly higher pain intensity before using the covariate than the group with the highest vitamin D.

There was statistically significant difference between the group with the most severe pain and the group with the mildest pain in the models 1 and 2. However, there was no statistically significant difference in the degree of pain compared to the group with the highest vitamin D.

In the $P$ for trend, $P = 0.879$ before using covariation, $P = 0.702$ in model 1 and $P = 0.606$ in model 2 were not statistically significant. Thus, the difference in pain level according to the level of vitamin D was not linear (Table 3).

Association between rheumatoid arthritis' EQ-5D index and vitamin D status

There was no statistically significant difference in the quality of life among the whole rheumatoid arthritis female according to their levels of vitamin D.

In fertile period rheumatoid arthritis female, the group with the lowest vitamin D had significantly lower quality of life before using covariance and model 1 than the group with the highest vitamin D. However, there was no statistically significant difference

### Table 1. Characteristics of participants

| Period              | Percentile | No. of unweighted participants | Age (yr) | Body mass index (kg/m$^2$) | Vitamin D (ng/mL) | Rheumatoid arthritis patients (%)a | Present smoking (%)a |
|---------------------|------------|--------------------------------|----------|----------------------------|-------------------|------------------------------------|----------------------|
| Female              | 1st        | 396                            | 39.02 ± 0.82 | 22.92 ± 0.22 | 8.52 ± 0.08 | 10.3                               | 8.8                  |
|                     | 2nd        | 402                            | 40.42 ± 0.82 | 22.78 ± 0.24 | 11.94 ± 0.04 | 9.0                                | 8.7                  |
|                     | 3rd        | 433                            | 41.14 ± 0.75 | 23.13 ± 0.22 | 14.86 ± 0.04 | 10.9                               | 6.3                  |
|                     | 4th        | 419                            | 43.45 ± 0.84 | 23.19 ± 0.22 | 17.91 ± 0.07 | 14.3                               | 6.9                  |
|                     | 5th        | 488                            | 49.56 ± 0.77 | 23.23 ± 0.18 | 25.97 ± 0.30 | 15.2                               | 6.0                  |
|                     | Total      | 2,162                          | 42.72 ± 0.32 | 23.05 ± 0.10 | 15.80 ± 0.19 | 12.0                               | 7.3                  |
| Fertile period      | 1st        | 220                            | 33.24 ± 0.77 | 22.50 ± 0.30 | 8.15 ± 0.09 | 6.1                                | 10.0                 |
|                     | 2nd        | 235                            | 32.41 ± 0.73 | 22.54 ± 0.43 | 11.29 ± 0.06 | 5.0                                | 8.8                  |
|                     | 3rd        | 241                            | 33.24 ± 0.63 | 22.47 ± 0.24 | 13.83 ± 0.06 | 6.3                                | 7.5                  |
|                     | 4th        | 233                            | 34.02 ± 0.66 | 22.44 ± 0.32 | 16.59 ± 0.07 | 7.0                                | 6.9                  |
|                     | 5th        | 250                            | 35.35 ± 0.72 | 22.70 ± 0.25 | 22.85 ± 0.34 | 4.2                                | 9.1                  |
|                     | Total      | 1,179                          | 33.66 ± 0.27 | 22.53 ± 0.14 | 14.54 ± 0.21 | 5.7                                | 8.5                  |
| Postmenopausal period | 1st      | 199                            | 57.24 ± 0.98 | 23.99 ± 0.30 | 9.44 ± 0.13 | 20.4                               | 5.9                  |
|                     | 2nd        | 192                            | 56.98 ± 0.95 | 23.82 ± 0.28 | 13.25 ± 0.07 | 18.5                               | 9.1                  |
|                     | 3rd        | 185                            | 57.74 ± 0.95 | 24.01 ± 0.28 | 16.53 ± 0.09 | 28.8                               | 5.2                  |
|                     | 4th        | 198                            | 58.46 ± 0.78 | 24.39 ± 0.29 | 20.55 ± 0.13 | 20.0                               | 3.3                  |
|                     | 5th        | 209                            | 59.41 ± 0.87 | 23.39 ± 0.24 | 29.75 ± 0.44 | 24.5                               | 3.8                  |
|                     | Total      | 983                            | 57.97 ± 0.31 | 23.92 ± 0.123 | 17.92 ± 0.294 | 22.4                               | 5.5                  |

Values are presented as mean ± standard error.
aPercentages were calculated by weighted number.
### Table 2. Association between rheumatoid arthritis and vitamin D status

| Period                  | Percentile | Crude                                           | Model 1                                        | Model 2                                        |
|-------------------------|------------|-------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                         |            | %\(^a\) OR (95% CI)\(^d\) P-value                | %\(^a\) OR (95% CI)\(^d\) P-value              | %\(^a\) OR (95% CI)\(^d\) P-value              |
| Female                  | 1st        | 20.0 0.629 (0.40–0.99) 0.043                   | 20.0 1.194 (0.74–1.93) 0.469                   | 20.0 1.167 (0.72–1.89) 0.530                   |
|                         | 2nd        | 19.9 0.551 (0.36–0.85) 0.007                   | 19.9 0.914 (0.58–1.44) 0.699                   | 19.9 0.913 (0.58–1.44) 0.696                   |
|                         | 3rd        | 20.0 0.686 (0.44–1.07) 0.007                   | 20.0 1.154 (0.72–1.86) 0.555                   | 20.0 1.153 (0.72–1.85) 0.556                   |
|                         | 4th        | 20.1 0.913 (0.57–1.74) 0.710                   | 20.1 1.330 (0.80–2.21) 0.269                   | 20.1 1.329 (0.80–2.20) 0.268                   |
|                         | 5th        | 20.0 Reference                                | 20.0 Reference                                | 20.0 Reference                                |
| Total\(^f\)             |            | 2,162                                         | 2,162                                         | 2,160                                         |
| Fertile period          | 1st        | 19.9 1.470 (0.65–3.34) 0.357                   | 19.9 1.647 (0.70–3.86) 0.249                   | 19.9 1.651 (0.70–3.88) 0.249                   |
|                         | 2nd        | 20.1 1.202 (0.52–2.78) 0.067                   | 20.1 1.405 (0.59–3.35) 0.442                   | 20.1 1.408 (0.59–3.37) 0.441                   |
|                         | 3rd        | 20.0 1.526 (0.65–3.58) 0.331                   | 20.0 1.750 (0.73–4.21) 0.211                   | 20.0 1.764 (0.73–4.27) 0.207                   |
|                         | 4th        | 20.0 1.686 (0.73–3.94) 0.219                   | 20.0 1.870 (0.78–4.48) 0.160                   | 20.0 1.887 (0.78–4.54) 0.156                   |
|                         | 5th        | 20.0 Reference                                | 20.0 Reference                                | 20.0 Reference                                |
| Total\(^f\)             |            | 1,179                                         | 1,179                                         | 1,179                                         |
| Postmenopausal period   | 1st        | 20.0 0.790 (0.45–1.40) 0.416                   | 20.0 0.864 (0.49–1.53) 0.615                   | 19.9 0.841 (0.47–1.49) 0.554                   |
|                         | 2nd        | 20.0 0.689 (0.41–1.19) 0.103                   | 20.0 0.773 (0.46–1.32) 0.342                   | 20.0 0.775 (0.46–1.30) 0.335                   |
|                         | 3rd        | 20.0 1.247 (0.67–2.33) 0.488                   | 20.0 1.400 (0.73–2.68) 0.310                   | 20.0 1.404 (0.74–2.68) 0.302                   |
|                         | 4th        | 19.9 0.768 (0.44–1.35) 0.358                   | 19.9 0.792 (0.45–1.38) 0.411                   | 20.0 0.796 (0.46–1.37) 0.412                   |
|                         | 5th        | 20.1 Reference                                | 20.1 Reference                                | 20.1 Reference                                |
| Total\(^f\)             |            | 983                                           | 983                                           | 981                                           |

Model 1 was adjusted for age. Model 2 was adjusted for age and body mass index.

\(^{a}\)Crude and each model’s odds ratios (ORs) and 95% confidence intervals (95% CIs) calculated by Complex samples logistic regression analysis. \(^{d}\)Percentage of participants in each percentiles were calculated by weighted number. \(^{f}\)Unweighted number.

### Table 3. Association between rheumatoid arthritis' visual analogue scale and vitamin D status

| Patient                        | Percentile | Crude                                           | Model 1                                        | Model 2                                        |
|--------------------------------|------------|-------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                |            | %\(^a\) Mean± SE\(^d\) P-value                 | %\(^a\) Mean± SE\(^d\) P-value               | %\(^a\) Mean± SE\(^d\) P-value               |
| Female rheumatoid arthritis patients | 1st        | 18.6 62.19±3.47 0.519                          | 18.6 60.23±3.55 0.400                       | 18.3 59.47±3.59 0.315                       |
|                                | 2nd        | 20.3 70.81±3.42                                | 20.3 69.87±3.36                              | 20.4 69.85±3.32                              |
|                                | 3rd        | 19.1 67.07±5.93                                | 19.1 67.19±5.82                              | 19.2 67.16±5.81                              |
|                                | 4th        | 20.3 65.11±3.98                                | 20.3 65.46±3.81                              | 20.3 65.44±3.80                              |
|                                | 5th        | 21.7 65.11±3.94                                | 21.7 67.25±3.88                              | 21.8 67.43±3.92                              |
| Total\(^f\)                    |            | 283                                            | 283                                           | 281                                           |
| Fertile rheumatoid arthritis patients | 1st        | 20.1 67.84±3.36 0.454                          | 20.1 68.29±2.73 0.504                       | 20.1 68.54±3.65 0.710                       |
|                                | 2nd        | 22.4 69.80±4.09                                | 22.4 69.99±4.15                              | 22.4 70.00±4.12                              |
|                                | 3rd        | 20.7 77.07±4.89                                | 20.7 76.40±4.33                              | 20.7 76.25±4.66                              |
|                                | 4th        | 18.5 54.98±13.36                               | 18.5 55.33±13.63                             | 18.5 55.37±13.79                             |
|                                | 5th        | 18.3 73.19±3.49                                | 18.3 72.88±3.32                              | 18.3 72.71±3.52                              |
| Total\(^f\)                    |            | 71                                             | 71                                            | 71                                            |
| Postmenopausal rheumatoid arthritis patients | 1st        | 17.3 59.55±4.17 0.031                          | 17.3 58.63±4.02 0.022                       | 16.8 57.65±4.07 0.015                       |
|                                | 2nd        | 19.6 64.75±4.44                                | 19.6 66.40±4.22                              | 19.7 66.33±4.12                              |
|                                | 3rd        | 21.5 75.85±3.85\(^e\)                         | 21.5 72.71±2.46                              | 21.7 72.79±2.49                              |
|                                | 4th        | 20.5 60.45±5.09                                | 20.5 62.42±5.56                              | 20.6 62.34±5.49                              |
|                                | 5th        | 21.1 62.84±5.32                                | 21.1 63.37±4.88                              | 21.2 63.34±4.85                              |
| Total\(^f\)                    |            | 212                                            | 212                                           | 210                                           |

Model 1 was adjusted for age. Model 2 was adjusted for age and body mass index.

\(^{a}\)Crude and each model’s means, standard errors, and P-value were calculated by complex samples general linear analysis. \(^{d}\)The percentage of participants in each percentiles were calculated by weighted number. \(^{e}\)Unweighted number. \(^{f}\)Compared to 5th percentile group.
in model 2. And, in postmenopausal period rheumatoid arthritis female group, the difference in quality of life according to the level of serum vitamin D was not statistically significant (Table 4).

**DISCUSSION**

Vitamin D levels in the body are most important to be produced by exposure to sunlight, which affects sun exposure, including skin pigmentation, clothing style, use of sunscreen, physical activity, and age. However, in case of inadequate exposure to sunlight increases the importance of food intake. And vitamin D levels are also affected by obesity, calcium, and parathyroid hormone (Lips et al., 2014). Obesity has been reported to reduce vitamin D (Derdemezis et al., 2011), and increasing age also reduces vitamin D, leading to a reduction in vitamin D to about 1/4 of that of younger adults (Holick et al., 2007).

However, in this study, postmenopausal period female with higher body mass index and higher age showed higher levels of vitamin D than fertile period female. Meta-analysis of vitamin D levels showed that there were differences according to age and region. Children and adolescent vitamin D levels were lower in the Asia/Pacific region than adults and elderly, however, children and adolescent vitamin D levels were higher in the Middle East/Africa region than adults and elderly (Hilger et al., 2014). Moreover, in Korea’s previous study, serum vitamin D levels were the lowest in the 20s and gradually increased with age up to 60s in both sexes (Nah et al., 2015). In industrialized countries, relatively younger women tend to use clothing or sunscreen agents, to reduce exposure to sunlight. In addition, the higher proportion of indoor occupation then undeveloped country may have reduced vitamin D in young cases (Nah et al., 2015). The elderly can maintain a sufficient level of vitamin D when exposed to the appropriate amount of ultraviolet light. Therefore, postmenopausal period female with higher occupation rate of occupations with a lot of outdoor activities such as agriculture and a higher rate of participation in outdoor activities such as sports may have a relatively long exposure time to sunlight (Lips et al., 2014).

The immune function of vitamin D is mediated by the vitamin D receptor. Vitamin D inhibits proliferation of activated B lymphocytes expressing vitamin D receptors and inhibits proliferation and differentiation of T cells. Vitamin D also has been shown to inhibit the production of interleukin (IL)-2, interferon gamma of T helper (Th) 1 cells and to inhibit the production of IL-17 of Th17 cells. Therefore, vitamin D has been reported to inhibit the

---

**Table 4. Association between rheumatoid arthritis’ EQ-5D index and vitamin D status**

| Patient                                      | Percentile | Crude Mean ± SE | P value | Model 1 Mean ± SE | P value | Model 2 Mean ± SE | P value |
|----------------------------------------------|------------|----------------|---------|------------------|---------|------------------|---------|
| Female rheumatoid arthritis patients        | 1st        | 19.6 ± 0.03    | 0.822   | 19.6 ± 0.03      | 0.675   | 19.3 ± 0.04      | 0.755   |
|                                             | 2nd        | 19.6 ± 0.02    | 2.00    | 20.1 ± 0.05      | 0.682   | 20.1 ± 0.02      | 0.682   |
|                                             | 3rd        | 20.1 ± 0.05    | 2.01    | 20.1 ± 0.03      | 0.682   | 20.2 ± 0.02      | 0.682   |
|                                             | 4th        | 20.1 ± 0.03    | 2.01    | 20.4 ± 0.03      | 0.682   | 20.4 ± 0.03      | 0.682   |
|                                             | 5th        | 20.4 ± 0.03    | 2.01    | 20.4 ± 0.03      | 0.682   | 20.4 ± 0.03      | 0.682   |
| Total                                       | 319        | 19.7 ± 0.01    | 0.025   | 19.7 ± 0.01      | 0.048   | 19.7 ± 0.01      | 0.165   |
| Fertile rheumatoid arthritis patients       | 1st        | 19.9 ± 0.01    | 2.01    | 19.9 ± 0.01      | 2.01    | 19.9 ± 0.01      | 2.01    |
|                                             | 2nd        | 20.4 ± 0.02    | 2.04    | 20.4 ± 0.02      | 2.04    | 20.4 ± 0.02      | 2.04    |
|                                             | 3rd        | 20.2 ± 0.12    | 2.02    | 20.2 ± 0.12      | 2.02    | 20.2 ± 0.11      | 2.02    |
|                                             | 4th        | 19.8 ± 0.01    | 2.01    | 19.8 ± 0.01      | 2.01    | 19.8 ± 0.01      | 2.01    |
| Total                                       | 80         | 19.7 ± 0.04    | 0.244   | 19.7 ± 0.04      | 0.570   | 19.3 ± 0.04      | 0.673   |
| Postmenopausal rheumatoid arthritis patients| 1st        | 20.2 ± 0.02    | 2.02    | 20.2 ± 0.02      | 2.02    | 20.3 ± 0.02      | 2.03    |
|                                             | 2nd        | 20.2 ± 0.03    | 2.02    | 20.2 ± 0.03      | 2.02    | 20.3 ± 0.03      | 2.03    |
|                                             | 3rd        | 20.0 ± 0.03    | 2.00    | 20.0 ± 0.04      | 2.01    | 2.01 ± 0.03      | 2.01    |
|                                             | 4th        | 19.9 ± 0.04    | 2.00    | 19.9 ± 0.03      | 2.00    | 2.00 ± 0.03      | 2.00    |
| Total                                       | 239        | 20.1 ± 0.04    | 0.244   | 20.1 ± 0.04      | 0.570   | 20.0 ± 0.04      | 0.673   |

Note: Model 1 was adjusted for age. Model 2 was adjusted for age and body mass index.

a) Crude and each model’s means, standard error, and P value were calculated by complex samples general linear analysis.

b) The percentage of participants in each percentiles were calculated by weighted number.

c) Unweighted number.

d) Compared to 5th percentile group.
Diseases, induced by B cells, peak at reproductive years in women with immune diseases in women of childbearing and postmenopausal age. Actions between the endocrine system and the immune system have been reported to affect the risk of rheumatoid arthritis. Interactions between the endocrine system and the immune system are known to be involved in the development of autoimmune rheumatoid arthritis (Abourazzak et al., 2015).

However, in clinical studies and research results, many cases were not In cross-sectional studies, there was no difference in the activity of arthritis, C-reactive protein, and erythrocyte sedimentation rate according to serum vitamin D levels in patients with inflammatory arthritis such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis (Braun-Moscovici et al., 2011). Preclinical rheumatoid arthritis may be caused by a subclinical inflammatory process as well as a decrease in vitamin D levels due to reduced sun exposure due to decreased physical activity and changes in dietary intake. However, it is unclear whether low levels of vitamin D increase the risk of rheumatoid arthritis or whether inflammatory conditions due to preclinical rheumatoid arthritis lower vitamin D levels (Hiraki et al., 2014).

Moreover, in Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHS II) cohort studies confirmed the relationship between the incidence of rheumatoid arthritis and vitamin D intake. There was no significant association between the incidence of rheumatoid arthritis and in NHS II, even with an intake of 400 IU/day or more of vitamin D, resulted in an increase in rheumatoid arthritis (Costenbader et al., 2008). A randomized double-blind placebo-controlled study of vitamin D in patients with rheumatoid arthritis for 12 months showed that vitamin D treatment was not effective in improving parathyroid hormone, bone mineral density, disease activity and cytokines in patients with rheumatoid arthritis (Hansen et al., 2015). The limitations of this study are that despite the data for many years, the actual number of patients with rheumatoid arthritis is not large enough, and seasonal effects, sun exposure time, use of drugs, such as disease modifying antirheumatic drugs or glucocorticoids, were not controlled.

The current recommendation for vitamin D supplements focuses on bone mineral density and fracture, and the Korean Society of Bone Metabolism (2015) recommends a daily intake of 800 IU of vitamin D. Although vitamin D has not been statistically associated with the development of rheumatoid arthritis, it has been reported that vitamin D may be an appropriate adjuvant therapy for patients with rheumatoid arthritis due to its low cost and harmlessness (Bahrami et al., 2014).

The results of this study showed that there was no difference in
the incidence of rheumatoid arthritis according to the level of vitamin D in Korean adult women and that there was no difference in pain and quality of life when rheumatoid arthritis occurred. However, it is necessary to clarify the relationship through a large-scale cohort study that reflects the results of recently reported genome studies. Considering the effect of vitamin D supply on bone density and fracture, and the low price, vitamin D administration with effectiveness analysis is also needed.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

Abourazzak FE, Talbi S, Aradoini N, Berrada K, Keita S, Hazry T. 25-Hydroxy vitamin D and its relationship with clinical and laboratory parameters in patients with rheumatoid arthritis. Clin Rheumatol 2015; 34:353-357.

Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol 2013;45:256-266.

Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130-136.

Aloia JF, Feuerman M, Yeh JK. Reference range for serum parathyroid hormone. Endocr Prat 2006;12:137-144.

Braun-Moscovici Y, Toledano K, Markovits D, Rozin A, Nahir AM, Balbir-Gurman A. Vitamin D level: is it related to disease activity in inflammatory joint disease? Rheumatol Int 2011;31:493-499.

Brennan P, Silman A. Breast-feeding and the onset of rheumatoid arthritis. Arthritis Rheum 1994;37:808-813.

Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: metabolism. Rheum Dis Clin North Am 2012;38:1-11.

Costenbader KH, Feskanich D, Holmes M, Karlson EW, Benito-Garcia E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis 2006;65:530-535.

Craig SM, Yu F, Curtis JR, Alarcón GS, Conn DL, Jonas B, Callahan LF, Smith EA, Moreland LW, Bridges SL Jr, Mikuls TR. Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. J Rheumatol 2010; 37:275-281.

Cutolo M, Plebani M, Shoenfeld Y, Adorini L, Tincani A. Vitamin D endocrine system and the immune response in rheumatic diseases. Vitam Horm 2011;86:327-351.

Cutolo M, Sulli A, Straub RH. Estrogen’s effects in chronic autoimmune/inflammatory diseases and progression to cancer. Expert Rev Clin Immunol 2014;10:31-39.

Dehghan A, Rahimpour S, Soleymani-Salehadi H, Owlia MB. Role of vitamin D in flare ups of rheumatoid arthritis. Z Rheumatol 2014;73:461-464.

Derdemezis CS, Voulgari PV, Drosos AA, Kiortsis DN. Obesity, adipose tissue and rheumatoid arthritis: coincidence or more complex relationship? Clin Exp Rheumatol 2011;29:712-727.

Doran MF, Crowson CS, O’Fallon WM, Gabriel SE. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study. J Rheumatol 2004;31:207-213.

Hansen KE, Bartels CM, Gangnon RE, Jones AN, Cogininer J. An evaluation of high-dose vitamin D for rheumatoid arthritis. J Clin Rheumatol 2014;20:112-114.

Haque UJ, Bartlett SJ. Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28:745-747.

Hilger J, Friedel A, Herr R, Rausch T, Roos F, Wahl DA, Pierroze DD, Weber P, Hoffmann K. A systematic review of vitamin D status in populations worldwide. Br J Nutr 2014;111:23-45.

Hiraki LT, Arkema EV, Cui J, Malpess S, Costenbader KH, Karlson EW. Circulating 25-hydroxyvitamin D level and risk of developing rheumatoid arthritis. Rheumatology (Oxford) 2014;53:2243-2248.

Holick MF, Chen TC, Lu Z, Sauter E. Vitamin D and skin physiology: a D-lightful story. J Bone Miner Res 2007;22 Suppl 2:S2-33.

Kerr GS, Sabahi I, Richards JS, Caplan L, Cannon GW, Reimold A, Thiele GM, Johnson D, Mikuls TR. Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity. J Rheumatol 2011;38:53-59.

Korea Centers for Disease Control and Prevention. Korea National Health and Nutrition Examination Survey (KNHANES). Seoul: Korea Centers for Disease Control and Prevention; 2015.

Krishnan AV, Swarni S, Peng L, Wang J, Moreno J, Feldman D. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010;151:32-42.

Lips P, van Schoor NM, de Jongh RT. Diet, sun, and lifestyle as determinants of vitamin D status. Ann N Y Acad Sci 2014;1317:92-98.

Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Iowa Women’s Health Study. Vitamin D intake is inversely associated with rheumatoid arthritis results from the Iowa Women’s Health Study. Arthritis Rheum 2004;50:72-77.

Nah EH, Kim S, Cho HL. Vitamin D levels and prevalence of vitamin D deficiency associated with sex, age, region, and season in Koreans. Lab Med Online 2015;5:84-91.

http://www.e-jer.org
Lee TH, et al. • Vitamin D and rheumatoid arthritis in Korean women

Pagan KD, Pagana TJ. Blood studies. In: Pagana KD; Pagana TJ. Mosby’s manual of diagnostic and laboratory tests. 4th ed. St. Louis: Mosby Elsevier; 2010; p. 380-383.

Picerno V, Ferro F, Adinolfi A, Valentini E, Tani C, Alunno A. One year in review: the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 2015;33:551-558.

Qin B, Yang M, Fu H, Ma N, Wei T, Tang Q, Hu Z, Liang Y, Yang Z, Zhong R. Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Res Ther 2015;17:86.

Rossini M, Maddali Bongi S, La Montagna G, Minisola G, Malavolta N, Bemini L, Cacace E, Sinigaglia L, Di Munno O, Adami S. Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res Ther 2010; 12:R216.

The Korean Society of Bone Metabolism. Physician’s guide for diagnosis & treatment of osteoporosis. Seoul: Korean Society of Bone Metabolism; 2015.